ISOLATED GLYCOPROTEIN IB ALPHA POLYPEPTIDE OF HUMAN THROMBOCYTES, FUSED PROTEIN, DNA MOLECULE (VERSIONS), EXPRESSION VECTOR (VERSIONS), CELL (VERSIONS), POLYPEPTIDE EXPRESSION METHOD, FUSED PROTEIN EXPRESSION METHOD, PHARMACEUTICAL COMPOSITION (VERSIONS), METHOD OF INHIBITING BODING OF BLOOD CELLS TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM, METHOD OF INHIBITING BONDING OF PROTEIN TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM AND DISORDER TREATMENT METHOD Russian patent published in 2010 - IPC C07K14/755 C12N15/12 C12N15/62 C12N1/00 C12N5/00 C12N15/63 C12P21/02 A61K38/37 A61P7/02 

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology and specifically to obtaining versions of glycoprotein IV alpha polypeptide of human thrombocytes (GPIbalpha) and can be used in medicine to treat vascular disorders. Using a recombinant technique, a polypeptide is obtained, which contains substitutes in SEQ ID NO:2 selected from: Y276F K237V C65S; K237V C65S; Y276F C65S; or Y276F Y278F Y279F K237V C65S. The obtained polypeptide is used to inhibit bonding of leucocytes to biological tissue or for treating disorders associated with activation of thrombocytes.

EFFECT: invention enables to obtain GPIbalpha polypeptide which bonds with von Willebrand factor with affinity which is at least 10 times higher than in natural GPIbα polypeptide, and also has low affinity for bonding with alpha-thrombin, lower aggregation and/or high resistance to proteolysis relative the polypeptide with SEQ ID NO:2.

41 cl, 3 dwg, 8 ex